Giredestrant plus everolimus significantly outperforms standard endocrine therapy in a post-CDK4/6 inhibitor setting.
Kalshi's pilot lets users wager on late-stage trial results. Physicians and researchers say the markets threaten trial ...
Electroacupuncture reduced liver fat and partly restored anti-inflammatory macrophages in mice, offering early signs that ...
Primary care practitioners report that using an AI scribe gives them back much-needed time that some use to see more patients ...
Study reports an AI model is as accurate as humans for generating preliminary echocardiogram interpretations, saving time for ...
By testing procedures, pathogens, and substances on themselves, these researchers generated discoveries that left a lasting ...
A decade after autologous hematopoietic stem-cell transplantation for systemic sclerosis, overall survival is seen in over two thirds of patients, and many do not need immunosuppressive therapy.
As of November 15, the long-delayed modifications for the iPLEDGE REMS for the teratogenic acne drug isotretinoin are in ...
Patients can be left with nonmedical expenses that are substantial for them, but a drop in the bucket for trial sponsors.
After 68 weeks of semaglutide treatment, more than a third of patients with severe obesity, as young as 6 years of age, no longer had a BMI indicative of the disease.
An international panel reaches consensus on just 35 of 105 clinical statements on ketamine and esketamine, leaving key ...
Women’s hormonal transitions remain underrepresented in neuroscience research, despite evidence linking changes in estrogen ...